PAVmed Reports Q3 2026 Financials, Lucid Diagnostics Medicare Funding for EsoGuard
PAVmed reported preliminary Q3 2026 financial results, highlighting Lucid Diagnostics' nationwide Medicare reimbursement for EsoGuard and progress at Veris Health. The company also announced FDA engagement for upcoming device submissions.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed